Biomarkers in ovarian cancer: To be or not to be

被引：39
作者：
Arend, Rebecca [1 ]
Martinez, Alba [1 ]
Szul, Tomasz [1 ]
Birrer, Michael J. [1 ]
机构：
[1] Univ Alabama Birmingham, 619 19th St S,176F 10390E, Birmingham, AL 35249 USA
来源：
CANCER | 2019年 / 125卷
关键词：
biomarkers; genomics; molecular signatures; ovarian cancer; targeted therapy; HOMOLOGOUS RECOMBINATION GENES; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; CARCINOMA; SURVIVAL; MUTATIONS; PATTERNS; SUBTYPES; THERAPY; REPAIR;
D O I：
10.1002/cncr.32595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Biomarkers are becoming increasingly important in the treatment of epithelial ovarian cancer. Recent work from many laboratories has begun to provide clinically meaningful biomarkers. This review summarizes the state of the science regarding biomarkers for stratifying early-stage patients into those who benefit from adjuvant treatment, primary debulking versus interval debulking, and specific targeted therapy. In addition, new molecular imaging technologies have been developed to allow the surgeon to resect subvisible tumor deposits. These efforts should increase clinical effectiveness while minimizing toxicities for patients.
引用
收藏
页码：4563 / 4572
页数：10
相关论文
共 50 条
  • [1] Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer
    Krzystyniak, J.
    Ceppi, L.
    Dizon, D. S.
    Birrer, M. J.
    ANNALS OF ONCOLOGY, 2016, 27 : 4 - 10
  • [2] Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer
    Kubelac, Paul
    Genestie, Catherine
    Auguste, Aurelie
    Mesnage, Soizick
    Le Formal, Audrey
    Pautier, Patricia
    Gouy, Sebastien
    Morice, Philippe
    Bentivegna, Enrica
    Maulard, Amandine
    Adam, Julien
    Achimas-Cadariu, Patriciu
    Leary, Alexandra
    CANCERS, 2020, 12 (03)
  • [3] Biomarkers for Predicting Complete Debulking in Ovarian Cancer: Lessons to Be Learned
    Fago-Olsen, Carsten Lindberg
    Ottesen, Bent
    Christensen, Ib Jarle
    Hogdall, Estrid
    Lundvall, Lene
    Nedergaard, Lotte
    Engelholm, Svend-Aage
    Antonsen, Sofie Leisby
    Lydolph, Magnus
    Hogdall, Claus
    ANTICANCER RESEARCH, 2014, 34 (02) : 679 - 682
  • [4] Biomarkers for Systemic Therapy in Ovarian Cancer
    Penzvalto, Zsofia
    Surowiak, Pawel
    Gyorffy, Balazs
    CURRENT CANCER DRUG TARGETS, 2014, 14 (03) : 259 - 273
  • [5] Ovarian Cancer: Biomarkers and Targeted Therapy
    Radu, Mihaela Raluca
    Pradatu, Alina
    Duica, Florentina
    Micu, Romeo
    Cretoiu, Sanda Maria
    Suciu, Nicolae
    Cretoiu, Dragos
    Varlas, Valentin Nicolae
    Radoi, Viorica Elena
    BIOMEDICINES, 2021, 9 (06)
  • [6] The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer
    Tonti, Noemi
    Golia D'Auge, Tullio
    Cuccu, Ilaria
    De Angelis, Emanuele
    D'Oria, Ottavia
    Perniola, Giorgia
    Lagana, Antonio Simone
    Etrusco, Andrea
    Ferrari, Federico
    Saponara, Stefania
    Di Donato, Violante
    Bogani, Giorgio
    Giannini, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
  • [7] Multi-Omics Analysis Identifying Key Biomarkers in Ovarian Cancer
    Li, Ju-Yueh
    Li, Chia-Jung
    Lin, Li-Te
    Tsui, Kuan-Hao
    CANCER CONTROL, 2020, 27 (01)
  • [8] Searching for a system: The quest for ovarian cancer biomarkers
    Rodland, Karin D.
    Maihle, Nita J.
    CANCER BIOMARKERS, 2010, 8 (4-5) : 223 - 230
  • [9] Biomarkers in Ovarian Cancer: Towards Personalized Medicine
    Lopez-Portugues, Carlos
    Montes-Bayon, Maria
    Diez, Paula
    PROTEOMES, 2024, 12 (01)
  • [10] Biomarkers of drug resistance in ovarian cancer - an update
    Davidson, Ben
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2019, 19 (06) : 469 - 476
12345